Skip to main content
SHANGHAI MICROPORT EP MEDTECH CO., LTD. logo

SHANGHAI MICROPORT EP MEDTECH CO., LTD. — Investor Relations & Filings

Ticker · 688351 ISIN · CNE100005PG9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 362 across all filing types
Latest filing 2024-06-18 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688351

About SHANGHAI MICROPORT EP MEDTECH CO., LTD.

https://www.everpace.com/

SHANGHAI MICROPORT EP MEDTECH CO., LTD. focuses on the research, development, and commercialization of medical devices for cardiac electrophysiology. The company provides a comprehensive suite of products for the diagnosis and treatment of cardiac arrhythmias, including 3D cardiac mapping systems, diagnostic catheters, and radiofrequency ablation catheters. Its core technology, the Columbus 3D EP Navigation System, enables precise localization and visualization of catheters within the heart. The product line also encompasses irrigation pumps and ablation generators designed to support minimally invasive procedures. The company aims to deliver integrated solutions that improve clinical outcomes for patients with rhythm disorders through advanced mapping and therapeutic technologies.

Recent filings

Filing Released Lang Actions
北京世辉律师事务所关于上海微创电生理医疗科技股份有限公司2023年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2023 Annual General Meeting (AGM) of Shanghai MicroPort EP MedTech Co., Ltd. It details the legality and validity of the AGM's convening, attendance, voting procedures, and results. The document does not contain financial statements or management discussion but focuses on the legal compliance and voting outcomes of the AGM. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at general meetings. The document length is over 5,000 characters and contains detailed voting results, not just an announcement of a report publication or a brief notice. Therefore, the correct classification is DVA with high confidence.
2024-06-18 Chinese
关于2023年年度报告信息披露监管问询函的回复公告
Annual Report Classification · 95% confidence The document is a detailed reply to a regulatory inquiry regarding the company's 2023 Annual Report. It contains extensive financial data for the fiscal year 2023, including revenue, profit, cost, product sales breakdown, and comparisons with industry peers. It also includes management explanations and auditor's verification related to the annual financial results. The document references the 2023 Annual Report and provides detailed financial and operational analysis, which is characteristic of an Annual Report or a detailed regulatory response related to it. The length (15,000 characters) and depth of financial data confirm it is not a brief announcement or a certification letter. Therefore, this document is best classified as an Annual Report (10-K equivalent). FY 2023
2024-06-17 Chinese
关于上海微创电生理医疗科技股份有限公司2023年年度报告的信息披露监管问询函回复的核查说明
Annual Report Classification · 95% confidence The document is a detailed response from Da Hua Certified Public Accountants to a regulatory inquiry from the Shanghai Stock Exchange regarding the 2023 annual report of Shanghai MicroPort EP MedTech Co., Ltd. It contains extensive financial data, analysis of revenue, costs, profit margins, and explanations for changes in financial performance over multiple years. The document includes auditor's verification and conclusions about the company's financials for the 2023 fiscal year. The presence of detailed financial statements, auditor's opinions, and the focus on the annual report content indicates this is related to the Annual Report itself rather than a mere announcement or a certification. Therefore, the document should be classified as an Annual Report (10-K). FY 2023
2024-06-17 Chinese
关于上海证券交易所《关于上海微创电生理医疗科技股份有限公司2023年年度报告的信息披露监管问询函》有关事项之核查意见
Annual Report Classification · 95% confidence The document is a detailed response from a securities company (华泰联合证券有限责任公司) to an inquiry letter issued by the Shanghai Stock Exchange regarding the 2023 Annual Report of 上海微创电生理医疗科技股份有限公司. It contains extensive financial data, business performance analysis, revenue breakdowns, cost and margin explanations, and comparisons with industry peers. The document discusses the company's 2023 fiscal year results in depth, including revenue, net profit, cost structure, and other financial metrics. The presence of detailed financial statements and management explanations about the annual period clearly indicates this is the actual Annual Report or a part of it, not just an announcement or a certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-06-17 Chinese
2023年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2023 年年度股东大会会议资料" which translates to "2023 Annual General Meeting (AGM) Meeting Materials." It contains detailed agenda items for the 2023 AGM, including reports from the board of directors, supervisory board, independent directors, annual report and summary, financial statements, profit distribution plan, and other proposals to be discussed and voted on during the AGM. The document also includes meeting procedures, voting instructions, and legal compliance notes. The content is consistent with materials prepared and distributed for an Annual General Meeting to inform shareholders and facilitate the meeting. It is not the annual report itself, nor an announcement of the report, but the meeting materials for the AGM. Therefore, the correct classification is AGM Information (AGM-R).
2024-06-11 Chinese
关于部分募集资金投资项目变更及延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai MicroPort EP MedTech Co., Ltd. regarding changes and delays in some of its fundraising investment projects. It details the original fundraising, the investment projects, the usage of funds up to a certain date, and the proposed adjustments to the investment amounts and timelines. It includes opinions from the supervisory board and the sponsor, and mentions that the changes require shareholder approval. The document is focused on the use and management of raised capital funds and changes to investment projects funded by those raised funds. It is not a full financial report, earnings release, or management discussion, but rather an update on capital usage and project changes related to fundraising. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is sufficient and contains substantive details about the fundraising and investment changes, not just an announcement of a report or a certification. Therefore, the appropriate classification is CAP with high confidence.
2024-05-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.